Abstract
(N Engl J Med. 2018;379:907–909) Ensuring that a pregnant woman has access to potentially life-saving treatments while safeguarding her fetus is a delicate balancing act that requires careful evaluation of risks and benefits to both the mother and fetus. In the present perspective article, Rasmussen and colleagues discuss the recent safety signal released by multiple organizations regarding the use of dolutegravir, an antiretroviral medication, during pregnancy and the potential for neural tube defects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
